VERA Vera Therapeutics Inc
Company Analysis
Latest News
Vera Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Vera Therapeutics is expected to report a Q2 2026 loss of $1.60 per share on zero revenue, while the stock currently trades at $32.02 against an average...
🟢 Vera Therapeutics is trading 6.43% up today ahead of second-quarter results
Vera Therapeutics is trading at $32.30, up +6.43% during the August 6, 2026 session, with the move potentially reflecting positioning around scheduled...
🔴 Vera Therapeutics is trading 4.1% down today as investors turn cautious ahead of earnings
Vera Therapeutics is trading 4.08% down at $30.95 as investors turn cautious and adjust positions ahead of the company's August 6 earnings report. • The move...
Vera Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Vera Therapeutics is expected to report a Q2 2026 net loss of $1.60 per share on revenue of $1.28 million, with its current stock price of $35.45 trading...
🔴 Vera Therapeutics is trading 4.2% down today amid a broad biotech selloff
Vera Therapeutics is trading at $31.65 (down 4.2%) amid a broad selloff in the biotech sector and mixed overall market conditions. • The move appears driven...
🔴 Vera Therapeutics is trading 5.6% down today despite a broader biotech sector rally
Vera Therapeutics is trading 5.6% down at $33.24 today despite a lack of fresh news and a broader biotech sector rally. • The move appears to be driven by...
🔴 Vera Therapeutics is trading 4.1% down today on profit taking after its post-FDA approval rally
Vera Therapeutics is trading 4.1% down at $36.93 as the stock undergoes short-term profit taking and consolidation following a significant rally earlier this...
🔴 Vera Therapeutics is trading 4.1% down today on profit-taking after its recent FDA-driven rally
Vera Therapeutics is trading 4.1% down at $40.76 as the stock undergoes consolidation following a significant rally earlier in July. • The stock's recent...
🟢 Vera Therapeutics is trading 4% up today following recent FDA approval of its IgA nephropathy drug
Vera Therapeutics is trading 4% up at $43.16 as momentum continues from the recent FDA accelerated approval of its IgA nephropathy drug, atacicept...
Vera Therapeutics downgraded to Sell, facing stiff competition for TRUTAKNA
Analysts downgraded Vera Therapeutics from Hold to Sell following the FDA's accelerated approval of its IgAN treatment, TRUTAKNA. The report cites a crowded...
🔴 Vera Therapeutics is trading 5.4% down today on profit-taking after TRUTAKNA FDA approval
Vera Therapeutics is trading 5.38% down today at $40.16 following a sharp post-approval pullback as investors lock in gains. • The decline is characterized as...
🔴 VERA is trading 4.9% down today on profit-taking following its FDA approval rally
VERA is trading at $40.86 (4.9% down) as investors take profits following a sharp rally sparked by the FDA’s accelerated approval of its IgA nephropathy drug,...
🔴 VERA is trading 4.6% down today on profit-taking after FDA approval surge
VERA is trading at $41.00 (4.6% down) in pre-market as investors lock in gains following the FDA's accelerated approval of its IgA nephropathy drug, atacicept...
🟢 VERA is trading 5% up today as investors position ahead of FDA decision on atacicept
VERA is trading 5% up at $42.14 as investors position ahead of a key FDA decision for its IgA nephropathy treatment, atacicept. • The Biologics License...
🟢 VERA is trading 4.8% up today ahead of FDA PDUFA date for atacicept
VERA is trading 4.8% up at $42.04 as traders position ahead of the FDA’s PDUFA action date for its IgA nephropathy drug, atacicept. - The Biologics License...
🟢 VERA is trading 5.5% up today ahead of pivotal FDA action date for atacicept
VERA is trading 5.5% up today at $41.90 in pre-market action as traders position ahead of a pivotal FDA action date for its lead IgA nephropathy drug,...
🔴 VERA makes sharp 12.1% drop
VERA is trading at $37.51, down 12.1% versus the comparison close of $42.66 during regular trading. This is a price-movement alert; no separate...
🔴 VERA is trading 5.7% down today after no clear company-specific catalyst
VERA is trading at 5.7% down now at $40.22 after no clear company-specific catalyst surfaced in the available news flow. The stock’s move appears consistent...
🟢 VERA is trading 5.7% up today, extending a multi-day rally on atacicept optimism
VERA is trading 5.7% up at $44.88 in pre-market, extending a strong multi-day rally fueled by ongoing positive sentiment around its lead drug, atacicept. •...
🟢 VERA extends move to 5.3% up
VERA is trading at $42.65, up 5.3% versus the comparison close of $40.50 during regular trading. This is a price-movement alert; no separate company-specific...